Traci McCarty | BioMarin Pharmaceutical, Inc. |
Jean-Jacques Bienaimé | BioMarin Pharmaceutical, Inc. |
Daniel K. Spiegelman | BioMarin Pharmaceutical, Inc. |
Henry J. Fuchs, M.D. | BioMarin Pharmaceutical, Inc. |
Jeffrey Robert Ajer | BioMarin Pharmaceutical, Inc. |
Robert A. Baffi | BioMarin Pharmaceutical, Inc. |
Salveen Richter | Goldman Sachs & Co. LLC |
Cory W. Kasimov | JPMorgan Securities LLC |
Ying Huang | Bank of America Merrill Lynch |
David N. Lebowitz | Morgan Stanley & Co. LLC |
Christopher J. Raymond | Piper Jaffray & Co. |
Martin Auster | Credit Suisse Securities (NYSE:USA) LLC |
Andrew Peters | Deutsche Bank Securities, Inc. |
Joseph P. Schwartz | Leerink Partners LLC |
Kennen MacKay | RBC Capital Markets LLC |
Phil Nadeau | Cowen & Company |
Ashiq Mubarack | William Blair & Co. LLC |
Laura Chico | Raymond James & Associates, Inc. |
Good afternoon and welcome to the first quarter financial results conference call. My name is John and I'll be facilitating the audio portion of today's interactive broadcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. At this time I would like to turn this call over to Ms.